Proprotein convertase subtilisin–kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment

• Published in: Atherosclerosis 2013-02, Vol.226 (2), p.459-465
• Main Authors: Kwakernaak, Arjan J, Lambert, Gilles, Slagman, Maartje C.J, Waanders, Femke, Laverman, Gozewijn D, Petrides, Francine, Dikkeschei, Bert D, Navis, Gerjan, Dullaart, Robin P.F
• Format: Article
• Language: English
• Subjects: Adult; Antiproteinuric treatment; atherosclerosis; Atherosclerosis (general aspects, experimental research); Biological and medical sciences; Blood and lymphatic vessels; body mass index; Cardiology. Vascular system; Cardiovascular; Chronic kidney disease; correlation; Diet, Sodium-Restricted; Female; General and cellular metabolism. Vitamins; high density lipoprotein cholesterol; Humans; kidneys; LDL cholesterol; Lipoproteins - blood; Lipoproteins - drug effects; Lisinopril - therapeutic use; low density lipoprotein cholesterol; low sodium diet; Male; Medical sciences; metabolism; Middle Aged; nephrosis; Non-HDL cholesterol; patients; Pharmacology. Drug treatments; Proprotein Convertase 9; Proprotein convertase subtilisin–kexin type 9; Proprotein Convertases - blood; Proteinuria; Proteinuria - blood; Proteinuria - drug therapy; Proteinuria - enzymology; Serine Endopeptidases - blood; sodium; Tetrazoles - therapeutic use; Valine - analogs & derivatives; Valine - therapeutic use; Valsartan
• ISSN: 0021-9150; 1879-1484
• DOI: 10.1016/j.atherosclerosis.2012.11.009

Abstract Objective LDL-receptor deficiency may provide a mechanism which contributes to atherogenic lipoprotein abnormalities in experimental nephrosis and in humans with glomerular proteinuria. The proprotein convertase subtilisin–kexin type 9 (PCSK9) pathway plays a key role in lipoprotein metabolism by promoting LDL-receptor degradation. We tested whether plasma PCSK9 is elevated in proteinuric states, and determined relationships of PCSK9 with lipoprotein responses to proteinuria reduction. Methods Thirty-nine kidney patients (e-GFR 61 ± 29 mL/min/1.73 m2 , proteinuria 1.9 [0.9–3.3] g/day; 19 on statin treatment) were studied during 2 randomized double-blind 6-week periods on either lisinopril (40 mg/day) and a regular sodium diet (194 ± 49 mmol Na+/day; baseline treatment) or lisinopril plus valsartan (320 mg/day) and a low sodium diet (102 ± 52 mmol Na+ /day; maximal treatment), and compared to age- and sex-matched controls. Maximal treatment decreased proteinuria to 0.5 [0.3–1.1] g/day ( P